Amplification of Her-2 has been described in tissue samples from different malignancies such as breast cancer, gastric cancer, and ovarian cancer.3,7 Investigations have also correlated Her-2 overexpression with poor prognosis in patients with ovarian and breast cancer.8 Here, ERBB2 is linked to ovarian cancer.